Breaking Finance News

Stifel Nicolaus announced Abbott Laboratories (NYSE:ABT), boosting its stock price target to $63.00 today

In a report released on 10/19/2017 Stifel Nicolaus increased the stock price target of Abbott Laboratories (NYSE:ABT) from $58.00 to $63.00 reporting a possible upside of 0.13%.

Just yesterday Abbott Laboratories (NYSE:ABT) traded 1.29% higher at $55.92. Abbott Laboratories’s 50-day moving average is $52.94 and its 200-day moving average is $48.37. The last stock price is up 15.29% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.03% over the same time period. 9,044,529 shares of ABT traded hands, up from an average trading volume of 5,609,800

Recent Performance Chart

Abbott Laboratories (NYSE:ABT)

Abbott Laboratories has PE ratio of 78.11 with a one year low of $37.38 and a one year high of $56.60 and has a market capitalization of $0.

A total of 15 analysts have released a report on Abbott Laboratories. Six analysts rating the company a strong buy, eight analysts rating the company a buy, six analysts rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of $46.73.

General Company Details For Abbott Laboratories (NYSE:ABT)

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States. Its Diagnostic Products include a range of diagnostic systems and tests. Its Nutritional Products include a range of pediatric and adult nutritional products. Its Company's Vascular Products include a range of coronary, endovascular, vessel closure and structural heart devices for the treatment of vascular disease. The Company, through St. Jude Medical, Inc., also offers products, such as rhythm management products, electrophysiology products, heart failure related products, vascular products, structural heart products and neuromodulation products.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.